Beta
195241

Effect of COVID-19 on Hemoglobin: Theories and Recommended Drugs

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Section B: Pharmaceutical Analytical & Organic Chemistry, Medicinal & Biochemistry

Abstract

COVID-19 has affected over 110 million patients worldwide till February 2021. Scientists seek to understand the pathophysiology and proposed several theories. COVID-19 severe clinical phenomena occurred due to cytokine storms that cause hypochlorous acid (HOCl) production. HOCl has several harmful effects on hemoglobin, like heme degradation and iron overload toxicity. There are two theories about the attack of COVID-19 on Hemoglobin. One widely shared hypothesis based on the docking model, recommended that SARS-CoV-2 proteins ORF1ab and ORF3a bind to hemoglobin protein, changing heme to ORF10, resulting in the breakdown of the heme into iron and Protoporphyrin IX (PPIX), causing the loss of hemoglobin function and iron toxicity. Objection theory depends on comparing the experimental analysis between patients with COVID-19 and acute respiratory distress syndrome (ARDS) patients. The results showed that COVID-19 patients were not showing any hemolytic anemia or altering the hemoglobin-oxygen dissociation curve and hence, COVID-19 has no role in the removal of iron and oxygen delivery. In addition, there is a hypothesis that hemoglobin structure plays a role in the physiopathology of COVID- 19 disease. In children a high fetal hemoglobin levels leading to a decrease in the mortality rate with COVID-19. Another hypothesis linked between the blood grouping and the risk of developing COVID-19 infection.  O group persons have a lower chance for infection. From all the previous studies, many drugs formulated like fetal hemoglobin inducers, Iron chelators, and Lactoferrin represents options for the treatment of COVID-19. The present review is an attempt to describe some hypothesizes related to the Hemoglobin theory. I n addition to information about some new therapies used in the treatment of COVID-19.

DOI

10.21608/aprh.2021.79803.1134

Keywords

Hemoglobin, COVID-19, Iron chelators

Authors

First Name

Zeinab

Last Name

Hassan

MiddleName

A.

Affiliation

Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Helwan, Egypt.

Email

htaha1978@gmail.com

City

-

Orcid

-

First Name

Mohamed

Last Name

Ahmed

MiddleName

H.

Affiliation

Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Helwan, Egypt.

Email

-

City

-

Orcid

-

First Name

Hend

Last Name

Sanad

MiddleName

H.

Affiliation

Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Helwan, Egypt.

Email

-

City

-

Orcid

-

First Name

Ahmed

Last Name

Ali

MiddleName

S.

Affiliation

Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Helwan, Egypt.

Email

ahmed.salemali@pharm.helwan.edu.eg

City

cairo

Orcid

0000-0002-6737-4504

Volume

5

Article Issue

4

Related Issue

28395

Issue Date

2021-10-01

Receive Date

2021-06-08

Publish Date

2021-10-01

Page Start

377

Page End

386

Print ISSN

2357-0547

Online ISSN

2357-0539

Link

https://aprh.journals.ekb.eg/article_195241.html

Detail API

https://aprh.journals.ekb.eg/service?article_code=195241

Order

3

Type

Review Article

Type Code

358

Publication Type

Journal

Publication Title

Journal of Advanced Pharmacy Research

Publication Link

https://aprh.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023